Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care

Diemberger, Igor; Fantecchi, Elisa; Reggiani, Maria Letizia Bacchi; Martignani, Cristian; Angeletti, Andrea; Massaro, Giulia; Ziacchi, Matteo; Biffi, Mauro; Lip, Gregory Y.h.; Boriani, Giuseppe

DOI:

[10.1016/j.ijcard.2018.03.058](https://doi.org/10.1016/j.ijcard.2018.03.058)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Diemberger, I, Fantecchi, E, Reggiani, MLB, Martignani, C, Angeletti, A, Massaro, G, Ziacchi, M, Biffi, M, Lip, GYH & Boriani, G 2018, 'Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care', *International Journal of Cardiology*, vol. 261, pp. 73-77.
<https://doi.org/10.1016/j.ijcard.2018.03.058>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Published in International Journal of Cardiology on 14/03/2018

DOI: 10.1016/j.ijcard.2018.03.058

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care

Igor Diemberger, Elisa Fantecchi, Maria Letizia Bacchi Reggiani, Cristian Martignani, Andrea Angeletti, Giulia Massaro, Matteo Ziacchi, Mauro Biffi, Gregory Y.H. Lip, Giuseppe Boriani

PII: S0167-5273(17)38078-6
DOI: doi:[10.1016/j.ijcard.2018.03.058](https://doi.org/10.1016/j.ijcard.2018.03.058)
Reference: IJCA 26187

To appear in:

Received date: 29 December 2017
Revised date: 9 February 2018
Accepted date: 12 March 2018

Please cite this article as: Igor Diemberger, Elisa Fantecchi, Maria Letizia Bacchi Reggiani, Cristian Martignani, Andrea Angeletti, Giulia Massaro, Matteo Ziacchi, Mauro Biffi, Gregory Y.H. Lip, Giuseppe Boriani, Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ijca(2017), doi:[10.1016/j.ijcard.2018.03.058](https://doi.org/10.1016/j.ijcard.2018.03.058)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**ATRIAL FIBRILLATION AND PREDICTION OF MORTALITY BY
CONVENTIONAL CLINICAL SCORE SYSTEMS ACCORDING TO THE
SETTING OF CARE**

**Igor Diemberger¹, MD, PhD; Elisa Fantecchi², MD; Maria Letizia Bacchi
Reggiani¹, BSc; Cristian Martignani¹, MD, PhD; Andrea Angeletti¹, MD; Giulia
Massaro¹, MD; Matteo Ziacchi¹, MD, PhD; Mauro Biffi¹, MD, PhD; Gregory
Y.H. Lip^{3*}, MD, PhD; Giuseppe Boriani^{2*}, MD; PhD.**

¹Institute of Cardiology, Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy;

²Cardiology Division. Department of Diagnostics, Clinical and Public Health
Medicine. University of Modena and Reggio Emilia, Policlinico di Modena, Modena,
Italy; ³ Institute of Cardiovascular Sciences, University of Birmingham, Birmingham,
United Kingdom.

[*Joint Senior Authors]

Correspondence:

Dr Igor Diemberger,

Institute of Cardiology, Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna, Policlinico S.Orsola-Malpighi.

Via Massarenti n. 9, 40138 Bologna, Italy

Tel.: +39-051349858

Fax: +39-051344859

E-mail: igor.diemberger@unibo.it

Key words: outcomes, real world, registry, survival, arrhythmia

Word count: 2000

ABSTRACT

Background: Atrial fibrillation (AF) is associated with high morbidity and mortality, also amongst anticoagulated patients. Our aim was to evaluate the predictive role for long-term mortality of a series of risk stratification scores associated with cardiovascular or thromboembolic outcomes (CHADS₂, CHA₂DS₂-VASc, ATRIA, TIMI-AF), and bleeding complications (HAS-BLED) in an unselected population of patients with AF.

Methods: Single center, observational, prospective registry of consecutive patients with AF, undergoing clinical/echocardiographic evaluation in a University Hospital, as either in-patients or out-patients. We assessed the role of each single score as predictors of long-term survival according to clinical setting.

Results: We enrolled 1051 patients, mean age 72 ± 12 years, who were followed for 797 ± 298 days. All the tested scores showed a good performance in prediction of mortality, together with several clinical factors (older age, chronic heart failure, diabetes, renal impairment, previous transient ischemic attack, left ventricular ejection fraction). The values at C-statistics ranged between modest (0.608-0.684) of inpatients to good (0.708-0.751) in outpatients without any statistical difference between the scores, excepted a lower performance of HAS-BLED.

Conclusions: Risk scores currently adopted for decision making on starting oral anticoagulation provide good prediction of long-term survival in unselected AF patients, especially in the outpatient setting.

Introduction

Atrial fibrillation (AF) is associated with high morbidity and mortality, which is still evident amongst anticoagulated patients¹⁻⁵. To improve effective clinical decision-making several clinical scoring systems (see Supplementary Table 1) have been developed to stratify the risk of thromboembolic events⁶⁻⁸, bleeding complications⁹ risk of adverse cardiovascular events¹⁰ and the identification of patients for whom a therapeutic benefit of novel oral anticoagulants (NOACs) over Vitamin K antagonist (VKA)¹¹. Previous studies have shown that the CHADS₂ and CHA₂DS₂-VASc scores may have some predictive role for survival of AF and non-AF patients both in inpatient and outpatient settings¹²⁻¹⁷ but the adoption in non-AF patients has been criticized¹⁸.

Our aim was to evaluate the predictive role for long-term mortality of a series of clinical risk stratification scores associated with cardiovascular or thromboembolic outcomes (ATRIA, CHADS₂, CHA₂DS₂-VASc, TIMI-AF), and bleeding complications (HAS-BLED) in an unselected population of patients with AF, also considering the site of enrolment (inpatient vs. outpatient setting).

Materials and Methods

We performed a single centre observational, prospective registry including consecutive patients with a diagnosis of AF referred to a tertiary teaching Hospital. The study design has been previously reported¹⁹. In brief, we enrolled patients with ≥ 1 ECG-proved episode of AF within 1 year before screening. Patients were included if ≥ 18 years old and basic echocardiographic data were available (i.e. left ventricular ejection fraction, left atrial diameter and quantification of valvular dysfunctions). The

local ethical committee approved the study and written informed consent was obtained by all the participants. The investigation was conducted in accordance with the principles expressed in the Declaration of Helsinki.

Data collection was performed at patient inclusion (baseline) and at 1-year follow-up. Baseline evaluation considered: (a) patient demographics, (b) medical history, (c) AF characteristics, (d) AF-related symptoms, (e) AF management strategy, (f) standard laboratory assay and (g) complete pharmacological therapy. For each patient we calculated ATRIA, CHADS₂, CHA₂DS₂-VASc, HAS-BLED, and TIMI-AF scores (Supplementary table 1). The same evaluation was performed every 12 months for up to three years of follow-up. At each review check we also evaluated overall patient status and the events occurred since baseline, in particular: (a) hospital admissions, (b) cardiovascular interventions, (c) instrumental evaluations. Between the two fixed face to face checks we performed telephonic surveillance (between months 3 to 9 after each check) to improve compliance to the protocol. The same was performed to exclude death or major clinical events for patients not performing the periodical face to face check. To classify the mode of death we performed parents interview and revision of death certificate and all the available clinical records by two different operators.

Statistical analysis:

Continuous variables with normal distribution are expressed as means $\pm$ standard deviation (median and interquartile range (IQR) for continuous variables without normal distribution). Categorical variables are expressed as number of patients and frequencies/percentage. Comparisons between enrolment and follow-up data were performed using the paired Student's t-test for continuous normally distributed

variables, χ^2 -test for categorical variables and non parametric equivalent tests for other type of variables. Cox proportional hazards analysis was used to identify scores as independent predictors of overall mortality and the results are presented as hazard ratio (HR), confidence interval and p-value. Models building follows a backward-stepwise approach, the test of term significance is the Wald chi-square test with cutoff p value of 0.1 for removal and 0.05 for addition. The Harrell's C-statistic and the confidence intervals were used to assess the goodness of fit, or discriminatory value, of Cox regression models and to compare their predictive power. Kaplan-Meier curves for overall survival according to the various scoring systems were constructed. Data analysis was performed with the statistical software Stata/SE 14.2 for Windows (StataCorp LLC, College Station TX, USA) and SPSS 23.0 (SPSS Statistics/IBM Corp, Chicago IL, USA).

Results

We enrolled 1051 patients aged 72 ± 12 years. The main enrolment site was cardiology ward and day-hospital (71.1%) followed by outpatients clinic (28.9%). Baseline clinical and echocardiographic characteristics of the enrolled population are reported in table 1 according to outpatient/inpatient status at the time of enrolment. In general the most common subtype was permanent AF (44.8%) justifying a rate-control strategy in a significant proportion of the enrolled patients (65.0%). Moreover, 48.3% of the overall patients never experienced any typical AF-related symptom, with palpitations and dyspnoea being the most represented among the remaining subjects. Notably, inpatients were sicker with respect to outpatients, with a higher proportion of permanent AF and only in a minority of the patients AF was the principal cardiovascular problem leading to access to medical intervention.

The mean baseline values for the various clinical scores were as follows: ATRIA 5.6 ± 2.9 , CHADS₂ 2.0 ± 1.3 , CHA₂DS₂-VASc 3.7 ± 1.9 , HAS-BLED 2.0 ± 0.9 , and TIMI-AF 5.7 ± 2.1 .

After a mean follow-up of 797 ± 298 days (median 730 days; range 368-1102 days) 166/1051 (15.8%) patients died. The causes of death were as follows: non-cardiovascular (38.0%. Among them the leading causes were cancer, 12.7% of the total, infections 10.4% and trauma 3.6%), heart failure (30.7%), stroke (4.2%) other cardiovascular aetiologies (14.5%). In 21 patients (12.7%) the aetiology remained undetermined. Notably inpatients presented a higher overall death at follow-up without a significantly different cause of the event, despite a trend for non-cardiovascular causes in outpatients (Figure 1).

Univariate and multivariate regression

We first performed a univariate Cox regression analysis including all the tested scores together with the single characteristics included in these scores (supplementary table 2). Using the significant characteristics from the univariate analysis, we performed multivariate regression analysis among the single factors which showed six factors that were independently associated with overall survival (Model 1). Notably the mode of access to medical evaluation (inpatient vs. outpatient) presented a p value for interaction <0.05 for each score with exception of TIMI-AF, for which however was present a trend ($p=0.061$). Conversely, the presence/absence of anticoagulation (performed as a sensitivity analysis) was not associated with a significant p value for interaction for each scoring system included in the analysis. According to these findings we provided two additional model in the multivariate regression analysis for inpatient (Model 2) and outpatients (Model 3). Notably only left ventricular ejection fraction and diabetes were present in all the models.

Figure 2 shows Kaplan Meier curves for 1-year survival for each of the different scores divided into low to high risks categories, as defined in the literature²⁰⁻²².

Predictive value

We compared the five risk scores in predicting overall survival with C-Harrell test, together with the probability provided by the multivariate Cox regression analysis (used as a positive comparator). As show in table 2 the performance of the all scores for the prediction of death was good with exception of HAS-BLED score. Of note, the probability assessed by the model provided by the multivariate Cox regression analysis performed better than each score in general population, but this finding seems to be driven by the inpatient subgroup, while in outpatients the C statistic the model and “standard” score did not produce any significant difference.

Discussion

In our study we compared the five clinical risk scores used in current clinical practice for the management of patients with AF in their capability of predicting mortality in a relatively unselected prospectively enrolled group of AF patients. All scores showed a good performance in prediction of mortality using univariate Cox regression analysis, as did several individual factors included in their calculation: age, renal impairment, diabetes, heart failure, left ventricular ejection fraction and previous transient ischemic attack. Since the development of CHADS₂ several scoring systems have been developed for AF patients to improve risk stratification for several events: stroke, bleeding complications, cardiovascular events. However, we have no guide on how to integrate them in clinical practice. This is a relevant topic considering that the experts who were in charge of the last AF guidelines felt the need to modify the practical use of HAS-BLED (and other scoring system for stratifying the bleeding risk) since for many clinicians a high score was seen as a barrier to anticoagulation²³.

Few studies compared CHADS₂ and CHA₂DS₂-VASc scores for prediction of overall survival in more selected populations with or without AF¹²⁻¹⁴. The HAS-BLED score was also tested in one of these studies in a group of patients undergoing PCI²⁴ with a relatively lower performance with respect to CHADS₂ and CHA₂DS₂-VASc in accordance to our results.

Our results show that, beyond the stratification of the risk of stroke, two scores like CHADS₂ and CHA₂DS₂-VASc, which are based on a limited set of data, are effective in predicting overall mortality without the need for additional information such as laboratory tests (e.g. creatinine, proteinuria or haemoglobin) or echocardiography, which are less readily available especially in outpatient settings. In this view, the second most important result of our study is that prediction of long-term mortality was significantly affected by the setting (see Figure 1,2) as documented by the different factors included in the final multivariate models for inpatients and outpatients. This can be driven by the differences in the two subgroups in terms of AF type and comorbidities. But it can also be the effect of other factors (e.g. variability of renal function leading to greater imprecision in outpatients, or acute/subacute events leading to hospitalization). Notably, despite the deep differences in these two subgroups of patients all scores, with the exception of HAS-BLED, performed very well for prediction of mortality without a significant superiority of any of them. However, only in the outpatient settings the results were equivalent to the multivariate model. This is a very important result since it shows a simple scoring systems, like CHADS₂ and CHA₂DS₂-VASc, is as good as an ad-hoc score to predict mortality in an unselected population of AF outpatients. A further consideration has to be made on the possible differences in AF treatment between inpatient and outpatients that could also explain the different outcomes, in particular regarding thromboembolic

prophylaxis²⁵. Notably, in our cohort we found no difference between inpatient and outpatients in terms of anticoagulant prescription without interaction with the predictive role of each score, while our high prescription rate (respectively 90% vs. 86%; $p=NS$) reflects current trends in AF management, as reported by the EORP-AF registry²⁶, increasing transferability of our results. Conversely, the study by Mikkelsen et al. was related to a previous period (2002-2011) with a lower use of anticoagulation (about 60% for outpatient and 40% for inpatients). It could be obvious but it is relevant to consider that the results of all these scores vary with time leading to the question on how frequently should be reassessed each score in the specific patient. According to our results a re-evaluation every 12-24 months or soon after hospital admission should provide the best compromise. Moreover, in less stable patients more “complete” scores, like TIMI-AF, should be considered. However, further evaluation are needed to confirm a similar approach. Finally, several other risk factors are not included by the scores we considered (e.g. AF burden, atrial dilatation, additional comorbidities, neurohormones) that could potentially help in predicting long-term survival. Despite these considerations the practical implications of our findings are significant: in clinical practice this could improve personalization of patient follow-up by targeting a closer clinical monitoring to patients at increased risk of thromboembolic events. Moreover, the value of these scores can help comparing the risk of long-term mortality of different populations and/or subgroups²⁷.

Limitations

The most important limitation of our study is its observational nature and related to a single University Hospital. The sample size is relatively limited, with a relatively high mean value of CHA2DS2-VASc score therefore may be not fully generalizable to all AF patients, especially to less sick patients.

Conclusions

Clinical risk scores associated with cardiovascular or thromboembolic outcomes improve prediction of long-term survival in unselected AF patients. In particular, we found no difference in predicting value of simple scores (like CHADS2 and CHA2DS2-VASc) with respects to scores requiring integration of laboratory and echocardiography data. Their performance seems to be higher in outpatient (vs. inpatient) settings where personalization of patient monitoring can improve everyday clinical practice.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

FIGURE LEGENDS

Figure 1. Overall survival and cause of death according to clinical settings.

Legend: CV=cardiovascular; HF=heart failure; pts=patients.

Figure 2. Kaplan Meier curves for 1-year survival for each of the different scores divided into low to high risks categories according to clinical settings.

References

1. Lip, G. Y. H. *et al.* Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). *Eur. Heart J.* **35**, 3365–3376 (2014).

2. Freedman, B., Martinez, C., Katholing, A. & Rietbrock, S. Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. *JAMA Cardiol.* **1**, 366–8 (2016).
3. Fauchier, L. *et al.* Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. *Am. J. Med.* **129**, 1278–1287 (2016).
4. Diemberger, I. *et al.* The "Subtle" connection between development of cardiac implantable electrical device infection and survival after complete system removal: An observational prospective multicenter study. *Int. J. Cardiol.* **250**, 146–149 (2018).
5. Diemberger, I. *et al.* The effects of gender on electrical therapies for the heart: procedural considerations, results and complications: A report from the XII Congress of the Italian Association on Arrhythmology and Cardiac Stimulation (AIAC). *Europace* **19**, 1911–1921 (2017).
6. Gage, B. F. *et al.* Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* **285**, 2864–70 (2001).
7. Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. G. M. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. *Chest* **137**, 263–272 (2010).
8. Singer, D. E. *et al.* A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. *J. Am. Heart Assoc.* **2**, e000250–e000250 (2013).
9. Pisters, R. *et al.* A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. *Chest* **138**, 1093–1100 (2010).
10. Kornej, J. *et al.* The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. *Clin. Res. Cardiol.* **104**, 871–876 (2015).
11. Fanola, C. L. *et al.* A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. *Eur. Heart J.* **38**, 888–896 (2017).
12. Chao, T.-F. *et al.* CHADS2 and CHA2DS2-VASc Scores in the Prediction of Clinical Outcomes in Patients With Atrial Fibrillation After Catheter Ablation.

- J. Am. Coll. Cardiol.* **58**, 2380–2385 (2011).
13. Chua, S.-K., Lo, H.-M., Chiu, C.-Z. & Shyu, K.-G. Use of CHADS₂ and CHA₂ DS₂ -VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. *PLoS One* **9**, e111167 (2014).
 14. Larsen, T. B. *et al.* Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. *Circ. Cardiovasc. Qual. Outcomes* **5**, 335–42 (2012).
 15. Lahewala, S. *et al.* Atrial fibrillation: Utility of CHADS2 and CHA2DS2-VASc scores as predictors of readmission, mortality and resource utilization. *Int. J. Cardiol.* **245**, 162–167 (2017).
 16. Yoshihisa, A. *et al.* The CHA₂ DS₂ -VASc score as a predictor of high mortality in hospitalized heart failure patients. *ESC Hear. Fail.* **3**, 261–269 (2016).
 17. Temizer, O. *et al.* The Association between CHA2DS2-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. *Acta Cardiol. Sin.* **33**, 429–435 (2017).
 18. Wang, C.-L. CHA2DS2-VASc Score: A Simple But Not Appropriate Risk Score for Predicting Mortality Risk in Patients with Heart Failure. *Acta Cardiol. Sin.* **33**, 436–438 (2017).
 19. Boriani, G. *et al.* Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. *J. Cardiovasc. Med. (Hagerstown)*. **16**, 491–6 (2015).
 20. Aspberg, S. *et al.* Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. *Eur. Heart J.* **37**, 3203–3210 (2016).
 21. van den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G. M. & van Staa, T. P. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. *J. Am. Coll. Cardiol.* **66**, 1851–9 (2015).
 22. Shukla, A. & Curtis, A. B. Avoiding permanent atrial fibrillation: treatment

- approaches to prevent disease progression. *Vasc. Health Risk Manag.* **10**, 1–12 (2014).
23. Kirchhof, P. *et al.* 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* **18**, 1609–1678 (2016).
24. Puurunen, M. K. *et al.* CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. *Thromb. Res.* **133**, 560–6 (2014).
25. Mikkelsen, A. P. *et al.* Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. *Europace* **18**, 492–500 (2016).
26. Boriani, G. *et al.* Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. *Europace* (2017). doi:10.1093/europace/eux301
27. Proietti, M. & Lip, G. Y. Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. *Int. J. Cardiol.* **236**, 244–248 (2017).

ATRIAL FIBRILLATION AND PREDICTION OF MORTALITY BY CONVENTIONAL CLINICAL SCORE SYSTEMS ACCORDING TO THE SETTING OF CARE

I. Diemberger¹, MD, PhD; E. Fantecchi², MD; Maria Letizia Bacchi Reggiani¹, BSc; Cristian Martignani¹, MD, PhD; Andrea Angeletti¹, MD; Giulia Massaro¹, MD; Matteo Ziacchi¹, MD, PhD; Mauro Biffi¹, MD, PhD; G.Y.H. Lip^{3*}, MD, PhD; G. Boriani^{2*}, MD; PhD.

¹Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy;

²Cardiology Division. Department of Diagnostics, Clinical and Public Health Medicine. University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; ³ Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

[*Joint Senior Authors]

HIGHLIGHTS

- We found that five scoring systems showed a good performance in prediction of long-term mortality in a relatively unselected cohort of patients;
- No significant difference in prediction performance was seen among the five scores, with the exception of HASBLED;
- In particular, we found no difference in predicting value of simple scores (like CHADS2 and CHA2DS2-VASc) with respects to scores requiring integration of laboratory and echocardiography data.
- Prediction of long-term mortality is affected by the setting, with a better performance for all the scores in the outpatient settings;

Figure 1

Figure 2